| 1 | Canakinumab | 7件: Canakinumab; Canakinumab (acz885); Canakinumab (company code: acz885d); Canakinumab (investigational); Canakinumab (proposed); Canakinumab (who approval pending); Canakinumab injection [ilaris]; | D09315 |
1件: IL1B |
40件: AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Chagas disease (American trypanosomiasis), Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human cytomegalovirus infection, IL-17 signaling pathway, Inflammatory bowel disease (IBD), Inflammatory mediator regulation of TRP channels, Influenza A, Legionellosis, Leishmaniasis, MAPK signaling pathway, Malaria, Measles, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Necroptosis, Non-alcoholic fatty liver disease (NAFLD), Osteoclast differentiation, Pathogenic Escherichia coli infection, Pertussis, Prion diseases, Rheumatoid arthritis, Salmonella infection, Shigellosis, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Tuberculosis, Type I diabetes mellitus, Yersinia infection |
9件: 46, 56, 84, 106, 107, 108, 113, 266, 269 |